# Why RAPT Therapeutics Stock Is Crushing It Today

**URL:** https://tribe.getbaraka.com/t/why-rapt-therapeutics-stock-is-crushing-it-today/412
**Category:** Baraka Chat
**Tags:** investment
**Created:** [15 June 2021 09:03 UTC](https://tribe.getbaraka.com/t/why-rapt-therapeutics-stock-is-crushing-it-today/412 "2021-06-15T09:03:26Z")
**Posts on this page:** 1
**Page:** 1

<div class="post-metadata">

### Author: ![Neerab](https://sea1.discourse-cdn.com/flex019/user_avatar/tribe.getbaraka.com/neerab/32/63_2.png) [@Neerab](https://tribe.getbaraka.com/u/Neerab)
#### Post date: [15 June 2021 09:03 UTC](https://tribe.getbaraka.com/t/why-rapt-therapeutics-stock-is-crushing-it-today/412/1 "2021-06-15T09:03:26Z")

</div>

**RAPT Therapeutics** ([NASDAQ:RAPT](https://www.fool.com/quote/nasdaq/rapt-therapeutics-inc/rapt/)) stock was crushing it on Monday, with shares skyrocketing 110.4%. The huge gain came after the company announced positive top-line results from a phase 1b clinical study evaluating RPT193 in treating moderate-to-severe atopic dermatitis.

## So what

You’d expect that RAPT’s results from the early-stage study of RPT193 had to be fantastic for the [biotech stock](https://www.fool.com/investing/stock-market/market-sectors/healthcare/biotech-stocks/) to more than double. And they were.

Patients treated with the company’s experimental drug achieved a 36.3% improvement in the Eczema Area and Severity Index (EASI) score from baseline. That was more than twice the 17% improvement seen in patients on a placebo.

The story looked even better with patients experiencing a 50% improvement in EASI score – 42.9% of patients treated with RPT193 achieved this marked improvement compared to only 10% of patients in the placebo group.PT193 also achieved the primary efficacy endpoints on two other measurements: the validated Investigator Global Assessment (vIGA) and pruritis Numerical Rating Scale (NRS). The experimental drug appeared to be well tolerated in the early-stage clinical study, with no serious adverse events reported.

Investors were especially excited about these results because RPT193 is a once-daily oral treatment. If the drug eventually wins regulatory approval, it could have a competitive advantage over rival treatments that are administered via injection.

## Now what

RAPT Therapeutics now plans to advance RPT193 to a phase 2b study targeting atopic dermatitis. The company will also evaluate the therapy in a phase 2a study in treating asthma.